ATE446946T1 - Neues verfahren zur salzherstellung - Google Patents

Neues verfahren zur salzherstellung

Info

Publication number
ATE446946T1
ATE446946T1 AT07785845T AT07785845T ATE446946T1 AT E446946 T1 ATE446946 T1 AT E446946T1 AT 07785845 T AT07785845 T AT 07785845T AT 07785845 T AT07785845 T AT 07785845T AT E446946 T1 ATE446946 T1 AT E446946T1
Authority
AT
Austria
Prior art keywords
new process
producing salt
salt
producing
trialkylsilylhalogenide
Prior art date
Application number
AT07785845T
Other languages
English (en)
Inventor
Josef Wieser
Hannes Lengauer
Elfriede Klingler
Arthur Pichler
Hubert Sturm
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37450796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446946(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE446946T1 publication Critical patent/ATE446946T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seasonings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT07785845T 2006-06-27 2007-06-25 Neues verfahren zur salzherstellung ATE446946T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116134 2006-06-27
PCT/EP2007/005596 WO2008000418A2 (en) 2006-06-27 2007-06-25 New method for salt preparation

Publications (1)

Publication Number Publication Date
ATE446946T1 true ATE446946T1 (de) 2009-11-15

Family

ID=37450796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07785845T ATE446946T1 (de) 2006-06-27 2007-06-25 Neues verfahren zur salzherstellung

Country Status (14)

Country Link
US (1) US20100204470A1 (de)
EP (3) EP2032521B1 (de)
JP (1) JP2009541385A (de)
CN (1) CN101484411A (de)
AT (1) ATE446946T1 (de)
AU (1) AU2007264030B2 (de)
CA (1) CA2655061A1 (de)
DE (1) DE602007003024D1 (de)
DK (1) DK2032521T3 (de)
ES (1) ES2335369T3 (de)
PL (1) PL2032521T3 (de)
RU (1) RU2461542C2 (de)
SI (1) SI2032521T1 (de)
WO (1) WO2008000418A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
WO2008130630A2 (en) * 2007-04-16 2008-10-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of rimonabant hydrochloride and processes for preparation thereof
EP2218713A1 (de) * 2007-08-17 2010-08-18 Hetero Drugs Limited Vom Polymorph der Form B weitgehend freies Erlotinibhydrochloridpolymorph der Form A
EP2257556A1 (de) 2008-02-06 2010-12-08 Helm AG Prasugrelsalze mit verbesserten eigenschaften
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
EP2415774B1 (de) * 2009-03-31 2014-07-09 Shanghai Institute of Pharmaceutical Industry Kristalle aus essigsäure solvat von prasugrel-hydrobromat
EP2236509A1 (de) 2009-04-01 2010-10-06 Ragactives, S.L. Methode zur Herstellung von 1,3-difunktionalisierten Pyrrolidin-Derivaten
PT2473170T (pt) 2009-09-04 2019-08-23 Horizon Orphan Llc Utilização de levofloxacina em aerossol para tratamento de fibrose cística
EP2499118A2 (de) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Verfahren zur herstellung von erlotinibhydrochlorid form a und erlotinibhydrochlorid form b
CZ2009828A3 (cs) 2009-12-09 2011-06-22 Zentiva, K.S. Zpusob prípravy hydrochloridu 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu hydrochloridu) v polymorfní forme B
CN102212071B (zh) * 2010-04-08 2014-03-26 上海医药工业研究院 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法
PL2448945T3 (pl) 2010-04-08 2015-06-30 Teva Pharma Krystaliczne postacie soli prasugrelu
CN102342921B (zh) * 2010-08-01 2013-09-11 江苏正大天晴药业股份有限公司 普拉格雷氢溴酸盐醋酸合物的药物组合物
EP2447256A1 (de) * 2010-10-21 2012-05-02 Laboratorios Lesvi, S.L. Verfahren zur Gewinnung von Dronedaron
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
SG10201405403QA (en) 2011-03-03 2014-11-27 Cadila Healthcare Ltd Novel salts of dpp-iv inhibitor
SI2691083T1 (sl) * 2011-03-29 2017-12-29 Krka, D.D., Novo Mesto Farmacevtski sestavek sitagliptina
KR101766835B1 (ko) 2011-05-04 2017-08-09 에스프린팅솔루션 주식회사 화상형성장치 및 그 제어 방법
WO2013001514A1 (en) 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation
WO2013001457A1 (en) 2011-06-30 2013-01-03 Ranbaxy Laboratories Limited Novel salts of sitagliptin
US20140350023A1 (en) 2011-12-08 2014-11-27 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
EP2882291B1 (de) * 2012-08-07 2017-09-27 ZCL Chemicals Ltd. Verbessertes verfahren zur herstellung von memantin-hydrochlorid
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
PL402028A1 (pl) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Sposób wytwarzania postaci polimorficznej B chlorowodorku prasugrelu o czystości farmaceutycznej
CN103739500B (zh) * 2012-12-27 2016-03-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
ZA201401636B (en) * 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
CN103145628B (zh) * 2013-03-18 2015-04-22 齐鲁制药有限公司 一种厄洛替尼一水合物晶型i的制备方法
CN104072442B (zh) * 2013-03-28 2016-09-28 成都弘达药业有限公司 一种化合物及其制备方法
CN103396371B (zh) * 2013-08-26 2015-12-02 南京优科生物医药研究有限公司 一种盐酸埃罗替尼晶型a的制备方法
IN2014MU00651A (de) 2014-02-25 2015-10-23 Cadila Healthcare Ltd
WO2015170340A2 (en) * 2014-05-06 2015-11-12 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN107540634A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
JP2020535231A (ja) * 2017-09-26 2020-12-03 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規な塩および結晶
SG11202012095XA (en) * 2018-06-06 2021-01-28 Minoryx Therapeutics S L Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
EP3896063B1 (de) * 2018-12-14 2024-01-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Kristalline formen des syk inhibitors 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salz (1:1)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU46919B (sh) * 1988-07-13 1994-06-24 Krka Tovarna Zdravil N.Sol.O. Postupak za dobijanje derivata l-alanil-l-prolina
TW209865B (de) 1992-01-10 1993-07-21 Bayer Ag
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
SI9420052B (sl) 1993-09-15 2004-02-29 Syntex (U.S.A.) Inc. Kristalni brezvodni mikofenolatni mofetil in njegova intravenozna formulacija
DE19546249A1 (de) 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
NZ333197A (en) 1996-06-07 2001-03-30 Eisai Co Ltd Polymorphs of donepezil hydrochloride
DE59803108D1 (de) 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PT1728794E (pt) * 2000-07-06 2008-07-15 Ube Industries Sal de adição maleato de derivados de hidropiridina
MXPA03003459A (es) 2000-10-19 2005-04-29 Teva Pharma Base venlafaxina cristalina y polimorfos novedosos de clorhidrato de venlafaxina, procesos para su preparacion.
EP1330427A1 (de) 2000-10-31 2003-07-30 Ciba SC Holding AG Kristalline formen von venlafaxinhydrochlorid
HUP0400644A3 (en) * 2000-12-25 2009-06-29 Ube Industries Pharmaceutical compositions containing aspirin
DE10153345A1 (de) * 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
DE10161818A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Substituierte 1,5-Diaminopentan-3-ol-Verbindungen
DE10261091A1 (de) * 2002-12-20 2004-07-01 Grünenthal GmbH Gesättigte und ungesättigte Heteroarylcycloalkylmethyl-Amine
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1606262A1 (de) 2003-03-21 2005-12-21 Hetero Drugs Limited Neue kristalline formen von aripiprazol
WO2004098713A2 (en) * 2003-05-05 2004-11-18 Eli Lilly And Company Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)
US20060264635A1 (en) * 2003-08-05 2006-11-23 Chava Satyanarayana Process for the preparation of moxifloxacin hydrochloride
ES2319125T3 (es) 2003-11-20 2009-05-04 Chemi S.P.A. Polimorfos del clorhidrato del acido 1-ciclopropil-7-((s,s)-2,8-diazadiciclo(4.3.0)-non-8-il)-6-fluoro-1,4-dihidro-8-metoxi-4-oxo-3-quinolina carboxilico y metodos para la preparacion de los mismos.
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
CA2577610A1 (en) * 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands

Also Published As

Publication number Publication date
DK2032521T3 (da) 2010-01-25
AU2007264030A1 (en) 2008-01-03
WO2008000418A2 (en) 2008-01-03
EP2436381A1 (de) 2012-04-04
EP2145890B1 (de) 2012-08-01
EP2032521A2 (de) 2009-03-11
JP2009541385A (ja) 2009-11-26
CA2655061A1 (en) 2008-01-03
ES2335369T3 (es) 2010-03-25
US20100204470A1 (en) 2010-08-12
RU2461542C2 (ru) 2012-09-20
EP2145890A2 (de) 2010-01-20
EP2145890A3 (de) 2010-03-31
CN101484411A (zh) 2009-07-15
DE602007003024D1 (de) 2009-12-10
WO2008000418A3 (en) 2008-02-28
SI2032521T1 (sl) 2010-02-26
RU2009102279A (ru) 2010-08-10
AU2007264030B2 (en) 2012-04-05
PL2032521T3 (pl) 2010-05-31
EP2032521B1 (de) 2009-10-28

Similar Documents

Publication Publication Date Title
ATE446946T1 (de) Neues verfahren zur salzherstellung
EP1947190A4 (de) Verfahren zur herstellung von bernsteinsäure
ATE453630T1 (de) Verfahren zur herstellung von 2-aminothiazol-5- aromatischen carbonsäureamiden als kinaseinhibitoren
ATE544754T1 (de) Verfahren zur herstellung von ivabradinhydrochlorid
ZA200700833B (en) Method for the production of acrolein, acrylic acid, or a mixture thereof from propane
EA201100727A1 (ru) Новый способ получения производных аминокислот
DE602005006998D1 (de) Verfahren zur intensivierung der produktion von hong
ATE445019T1 (de) Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure
EP1900821A4 (de) Verfahren zur herstellung von l-aminosäure
DK2080808T3 (da) Fremgangsmåde til fremstilling af l-aminosyre
ATE546436T1 (de) Verfahren zur herstellung von 2-amino-5- cyanobenzoesäurederivaten
IL183591A0 (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
DE602005024566D1 (de) Verfahren zur herstellung von 2-amino-5-iodobenzoesäure
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren
DK2402306T3 (da) Fremgangsmåde til fremstilling af 5-aminolaevulinsyrehydrochlorid
DE602005025002D1 (de) Verfahren zur herstellung von brenztraubensäure
ATE551312T1 (de) Verfahren zur racematspaltung von zopiclon und zwischenprodukten
AP2007004270A0 (en) Process for preparing salts of hydrocyanic acid
DE602005013993D1 (de) Verfahren zur herstellung von 2-hydroxy-4-(methylthio)butansäure
DE112009001327A5 (de) Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen
ATE423096T1 (de) Verfahren zur herstellung von 2- azabicycloä3.3.0üoctan-3-carbonsäurederivaten
DE602004004679D1 (de) Verfahren zur herstellung des hemicalciumsalzes von (e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxy-6-heptensäure
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
DE602007001037D1 (de) Verfahren zur Herstellung von Acrylsäure
DE602006015458D1 (de) Verfahren zur herstellung eines carbonsäureamidderivats

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2032521

Country of ref document: EP